We observed dose-dependent increases of CS1 tumor lysis of >80% in CSPG4 CAR T cell treated cells at an E:T ratio of 1:1 versus <5% tumor lysis in the CD19 CAR T cell treated group. This evidence concerns the gene CSPG4 and neoplasm.